FIG. 1



SDS-PAGE analysis of PEG-modified hA5B7 Fab'

Samples of unmodified hA5B7 Fab' (lane 1), hinge-modified Fab' (lane 2), and randomly-modified Fab' (lane 3) were prepared with non-reducing sample buffer, and 1.5µg of each loaded onto a 4-20% gradient Tris-glycine gel. Standard protein markers (lane M) were also run. These comprised myosin (200kDa), beta-galactosidase (116.3kDa), phosphorylase b (97.4 kDa), bovine serum albumin (66.3kDa), glutamate dehydrogenase (55.4kDa), lactate dehydrogenase (36.5 kDa), carbonic anhydrase (31kDa), trypsin inhibitor (21.5kDa), lysozyme (14.4kDa), aprotinin (6kDa) and insulin B & A chains (3.5 &2.5kDa).
Following electrophoresis, the gel was stained with coomassie blue.

FIG. 2

Pharmacokinetics of 125-I labelled hA5B7 Fab' in rats



	t1/2α(h)	t1/2β(h)	AUC(0-∞)(%dose*h)
Fab'-hinge PEG	0.71	22.5	866
Fab'-random PEG	0.58	22.1	293
Fab'	0.33	10.0	47

FIG. 3



M 1 2 3

SDS-PAGE analysis of hTNF40 Fab'-PEG conjugates

Samples of hTNF40 Fab'-PEG (25kDa) prepared by random conjugation (lane 1), Fab'-PEG (25kDa) prepared by hinge attachment (lane 2), and Fab'-PEG (40kDa) prepared by hinge attachment (lane 3) were prepared with non-reducing sample buffer, and 1.5µg of each loaded onto a 4-20% gradient Tris-glycine gel. Standard protein markers (lane M) were also run. These comprised myosin (200kDa), beta- galactosidase (116.3kDa), phosphorylase b (97.4 kDa), bovine serum albumin (66.3kDa), glutamate dehydrogenase (55.4kDa), lactate dehydrogenase (36.5 kDa), carbonic anhydrase (31kDa), trypsin inhibitor (21.5kDa), lysozyme (14.4kDa), aprotinin (6kDa) and insulin B & A chains (3.5 &2.5kDa).
Following electrophoresis, the gel was stained with coomassie blue.

FIG. 4 Comparison between different PEG Fab' 's, Fab' of hTNF40.4, and hTNF40.4 in the L929 assay



FIG. 5 Pharmacokinetics of 125-I labelled hTNF40 Fab'-PEG in rats



FIG. 6 Pharmacokinetics of 111-In labelled hTNF40 in rats



FIG. 7



HPLC gel filtration of hTNF40 Fab', Fab'-PEG and Fab'(PEG)2

DuPont Zorbax GF-250 column run at 1ml/min in 0.2M phosphate buffer pH7.0

FIG.8 Pharmacokinetics of 125-I labelled TN3 in rats



FIG. 9 ECE15 : Pharmacokinetics of 125-I labelled TN3 in rats

Fab' PEGylated via the hinge with 25K PEG



FIG. 10 Pharmacokinetics of 125-I labelled hTNF40 Fab'-PEG in rats



SDS-PAGE analysis under non reducing conditions of Fab'-PEG (5kDa) prepared using a vinylsulphone or iodoacetamide reagent



1. Molecular weight marker proteins
2. Purified Fab' (also containing F(ab')2)
3. Fab'-PEG (5kDa, VS linker) reaction mix
4. Fab'-PEG (5kDa, IA linker) reaction mix
5. Fab'-PEG (5kDa, VS linker) reaction mix
6. Fab'-PEG (5kDa, IA linker) reaction mix

FIG. 11

FIG. 12

HPLC gel filtration analysis of (a) anti-PDGFβR Fab'-PEG reaction mix showing a peak of Fab'-PEG at 7.7 minutes and a peak of unreacted FAB' at 10.8 minutes.



FIG. 12

(b) HPLC analysis of purified Fab'-PEG.





FIG.13